- $384.53m
- $4.89bn
- $930.62m
- 44
- 44
- 77
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.58 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.41 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -29.33% | ||
| Return on Equity | -183.57% | ||
| Operating Margin | -155.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 937.76 | 1,117.6 | 1,079.72 | 961.52 | 930.62 | 932.25 | 960.57 | -1.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.
Directors
- Mark Tabak CHM (71)
- Dale White PRE (65)
- Jim Head CFO (56)
- Paul Galant CEX (53)
- Michael Kim SVP (55)
- Jeffrey Doctoroff SVP (52)
- Allen Thorpe LED (50)
- Michael Klein DRC (57)
- Glenn August IND (60)
- Richard Clarke IND (70)
- Anthony Colaluca IND (54)
- Paul Emery IND (35)
- C. Martin Harris IND (64)
- Julie Klapstein IND (66)
- P. Hunter Philbrick IND (41)
- William Veghte IND (53)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 30th, 2019
- Public Since
- February 10th, 2020
- No. of Shareholders
- 81
- No. of Employees
- 2,700
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
New York Stock Exchange- Shares in Issue
- 16,726,008
- Address
- 7900 Tysons One Place, Suite 400, MCLEAN, 22102
- Web
- https://www.claritev.com/
- Phone
- +1 2127802000
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for CTEV
Q1 2025 Claritev Corp Earnings Release
Q2 2025 Claritev Corp Earnings Release
Similar to CTEV
ABM Industries
New York Stock Exchange
ACCO Brands
New York Stock Exchange
Aris Water Solutions
New York Stock Exchange
BGSF
New York Stock Exchange
Block
New York Stock Exchange
FAQ
What is the Claritev share price?
As of Today at 19:58 UTC, shares in Claritev are trading at $22.99. This share price information is delayed by 15 minutes.
How has the Claritev share price performed this year?
Shares in Claritev last closed at $22.99 and the price had moved by +0.69% over the past 365 days. In terms of relative price strength the Claritev share price has underperformed the S&P500 Index by -7.06% over the past year.
What are the analyst and broker recommendations for Claritev?
The overall consensus recommendation for Claritev is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Claritev dividend yield?
Claritev does not currently pay a dividend.
Does Claritev pay a dividend?
Claritev does not currently pay a dividend.
When does Claritev next pay dividends?
Claritev does not currently pay a dividend.
How do I buy Claritev shares?
To buy shares in Claritev you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Claritev?
As of the previous close price of $22.99, shares in Claritev had a market capitalisation of $384.53m.
Where are Claritev shares listed?
Here are the trading details for Claritev:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: CTEV
What kind of share is Claritev?
Based on an overall assessment of its quality, value and momentum Claritev is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Claritev share price forecast for 2025?
The analyst consensus target price for shares in Claritev is $21.67. That is 5.74% below the last closing price of $22.99.
Analysts covering Claritev currently have a consensus Earnings Per Share (EPS) forecast of -$9.87 for the next financial year.
Find out moreWhat is the trend in the Claritev share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Claritev. Over the past six months, its share price has outperformed the S&P500 Index by +150.06%.
As of the last closing price of $22.99, shares in Claritev were trading +63.57% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Claritev PE Ratio?
The Claritev PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $22.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Claritev?
Claritev's management team is headed by:
- Mark Tabak - CHM
- Dale White - PRE
- Jim Head - CFO
- Paul Galant - CEX
- Michael Kim - SVP
- Jeffrey Doctoroff - SVP
- Allen Thorpe - LED
- Michael Klein - DRC
- Glenn August - IND
- Richard Clarke - IND
- Anthony Colaluca - IND
- Paul Emery - IND
- C. Martin Harris - IND
- Julie Klapstein - IND
- P. Hunter Philbrick - IND
- William Veghte - IND